###begin article-title 0
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Retroviral Host Restriction Factors APOBEC3G and APOBEC3F Localize to mRNA Processing Bodies
###end article-title 0
###begin p 1
###xml 1033 1038 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1120 1125 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1534 1539 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G is an antiviral host factor capable of inhibiting the replication of both exogenous and endogenous retroviruses as well as hepatitis B, a DNA virus that replicates through an RNA intermediate. To gain insight into the mechanism whereby APOBEC3G restricts retroviral replication, we investigated the subcellular localization of the protein. Herein, we report that APOBEC3G localizes to mRNA processing (P) bodies, cytoplasmic compartments involved in the degradation and storage of nontranslating mRNAs. Biochemical analysis revealed that APOBEC3G localizes to a ribonucleoprotein complex with other P-body proteins which have established roles in cap-dependent translation (eIF4E and eIF4E-T), translation suppression (RCK/p54), RNA interference-mediated post-transcriptional gene silencing (AGO2), and decapping of mRNA (DCP2). Similar analysis with other APOBEC3 family members revealed a potential link between the localization of APOBEC3G and APOBEC3F to a common ribonucleoprotein complex and P-bodies with potent anti-HIV-1 activity. In addition, we present evidence suggesting that an important role for HIV-1 Vif, which subverts both APOBEC3G and APOBEC3F antiviral function by inducing their degradation, could be to selectively remove these proteins from and/or restrict their localization to P-bodies. Taken together, the results of this study reveal a novel link between innate immunity against retroviruses and P-bodies suggesting that APOBEC3G and APOBEC3F could function in the context of P-bodies to restrict HIV-1 replication.
###end p 1
###begin title 2
Synopsis
###end title 2
###begin p 3
###xml 220 225 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 268 273 <span type="species:ncbi:9606">human</span>
###xml 464 469 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Successful replication of viruses and other intracellular pathogens in their respective host cells requires that they overcome a series of replication restrictions or "roadblocks" established by the cell. In the case of HIV-1, the ability of the virus to replicate in human cells is dependent on its ability to neutralize APOBEC3G, a DNA editing enzyme that incorporates into virions and renders them noninfectious. Although a potentially devastating inhibitor of HIV-1 replication, the virus evades APOBEC3G by inducing its degradation during virus assembly. APOBEC3G is also capable of inhibiting the replication of other retroviruses as well as the hepadnavirus hepatitis B, a DNA virus that replicates through an RNA intermediate, suggesting that APOBEC3G may function in cellular defense against a broad range of viral pathogens. Here, Rana and colleagues present their findings that APOBEC3G localizes to specialized compartments in the cytoplasm of mammalian cells known as mRNA processing (P) bodies, which function in the degradation and storage of cellular mRNA. Furthermore, they show that APOBEC3G assembles into a ribonucleoprotein complex with P-body proteins involved in translation, translation suppression, RNA interference, and mRNA decapping. These novel and exciting findings have broad-scale implications for APOBEC3G function and for the role of P-bodies in both cellular defense against viruses and retroviral assembly.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b001">1</xref>
###xml 381 384 381 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 402 403 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b002">2</xref>
###xml 498 499 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b001">1</xref>
###xml 500 501 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b003">3</xref>
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b004">4</xref>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b005">5</xref>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b006">6</xref>
###xml 571 572 571 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b007">7</xref>
###xml 30 35 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 395 400 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The successful propagation of HIV-1 through the human host has been linked to its ability to subvert and overcome innate cellular defense mechanisms that function by restricting replication of the virus at various points in the life cycle [1]. APOBEC3G is a (deoxy)cytidine deaminase originally discovered as the host restriction factor responsible for limiting the replication of vif-deficient HIV-1 [2] and has since been implicated in the restriction of a broad range of exogenous retroviruses [1,3,4], endogenous retroviruses [5,6], and the hepadnavirus hepatitis B [7].
###end p 5
###begin p 6
###xml 7 10 7 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b002">2</xref>
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b008">8</xref>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b011">11</xref>
###xml 383 384 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b003">3</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b010">10</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b012">12</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b015">15</xref>
###xml 500 501 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b003">3</xref>
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b008">8</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b012">12</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b015">15</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b016">16</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b017">17</xref>
###xml 756 759 756 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b018">18</xref>
###xml 836 838 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b020">20</xref>
###xml 996 998 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b021">21</xref>
###xml 999 1001 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b025">25</xref>
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 369 374 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 680 685 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 770 775 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 814 819 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1034 1039 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1282 1287 <span type="species:ncbi:9606">human</span>
###xml 1333 1338 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
During vif-deficient HIV-1 replication, APOBEC3G associates with Gag during viral assembly and is packaged into progeny virions [2,8-11]. Once packaged, APOBEC3G imposes a potent restriction on viral replication in the next target cell through a mechanism that results in genome degradation, incomplete cDNA synthesis, and a detrimentally high mutation rate within the HIV-1 genome [3,10,12-15]. These consequences of APOBEC3G packaging have largely been attributed to deamination of the viral cDNA [3,8-12,15,16]; however, a recent study demonstrated that APOBEC3G remains antiviral in the absence of enzymatic activity [17], suggesting that the capacity of APOBEC3G to restrict HIV-1 replication may extend beyond deamination. Although effective against vif-deficient HIV-1, APOBEC3G is neutralized by wild-type HIV-1 through Vif [18-20], which functions in concert with an E3 ubiquitin ligase complex to mediate the polyubiquitination and rapid degradation of APOBEC3G through the proteasome [21-25]. These findings illustrate how HIV-1 has evolved to deactivate an important innate cellular defense mechanism and suggest that therapeutic intervention to disrupt the APOBEC3G-Vif interaction, directly inhibit Vif function, and/or up-regulate APOBEC3G expression could allow the human host to naturally limit the proliferation of HIV-1.
###end p 6
###begin p 7
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b026">26</xref>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b027">27</xref>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b029">29</xref>
###xml 969 971 969 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b030">30</xref>
###xml 999 1001 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b031">31</xref>
###xml 1002 1004 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b032">32</xref>
###xml 1068 1070 1068 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b033">33</xref>
###xml 1071 1073 1071 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b039">39</xref>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b027">27</xref>
###xml 1099 1101 1099 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b028">28</xref>
###xml 1102 1104 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b040">40</xref>
###xml 413 418 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 577 582 <span type="species:ncbi:4932">yeast</span>
###xml 1188 1193 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Despite these significant advances in our understanding of APOBEC3G biology, there remained a considerable lack of detail concerning the subcellular context in which APOBEC3G functions. APOBEC3G has been shown to localize throughout the cytoplasm and to concentrate within punctate cytoplasmic bodies [26]. However, the identity or relevance of these cytoplasmic bodies toward the ability of APOBEC3G to restrict HIV-1 replication was unknown. In this report, we show that APOBEC3G cytoplasmic bodies are mRNA processing (P) bodies. P-bodies are found in the cytoplasm of both yeast and mammalian cells and constitute specialized compartments where nontranslating mRNAs accumulate and are subject to degradation or storage [27-29]. In addition to subcellular localization studies, we also present biochemical evidence that APOBEC3G localizes to a ribonucleoprotein (RNP) complex with other P-body proteins which have established functions in cap-dependent translation [30], translation suppression [31,32], RNA interference-mediated post-transcription gene silencing [33-39], and mRNA decapping [27,28,40]. Finally, we present studies that reveal a potential link between the potent anti-HIV-1 activities of APOBEC3G and APOBEC3F with their localization to P-bodies and results suggesting that a primary function of Vif could be to limit the localization of these proteins to P-bodies. Taken together, these findings reveal a novel relationship between innate cellular immunity against retroviruses and P-bodies.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
APOBEC3G Localizes to mRNA P-Bodies
###end title 9
###begin p 10
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b026">26</xref>
###xml 329 337 329 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g001">Figure 1</xref>
###xml 381 389 381 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g001">Figure 1</xref>
###xml 513 516 513 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 722 725 722 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b041">41</xref>
###xml 850 858 850 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g001">Figure 1</xref>
###xml 1220 1241 1220 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 1297 1298 1297 1298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1391 1412 1391 1412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 1536 1544 1536 1544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g001">Figure 1</xref>
###xml 1550 1551 1550 1551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g001">1</xref>
###xml 527 532 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 736 741 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1119 1124 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1144 1150 <span type="species:ncbi:9986">rabbit</span>
Recently, we reported that recombinant APOBEC3G localizes throughout the cytoplasm and to discrete cytoplasmic foci of unknown origin, which we referred to as cytoplasmic bodies [26]. This localization pattern was consistently observed when recombinant APOBEC3G was transiently expressed in either 293T cells (e.g., APO3G-YFP in Figure 1A, arrow) or HeLa cells (e.g., APO3G-YFP in Figure 1B, arrow), which renders these naturally permissive cell lines (i.e., cells that lack endogenous APOBEC3G) nonpermissive to vif-deficient HIV-1 replication (unpublished data). Similar analysis of HeLa cells that stably express APOBEC3G with a C-terminal c-Myc epitope tag (APO3G-Myc), which also renders these cells nonpermissive to vif-deficient HIV-1 replication [41], revealed that stably expressed recombinant APOBEC3G also localized to cytoplasmic bodies (Figure 1C, arrow). Taken together, these findings suggested a possible link between cytoplasmic bodies and the antiretroviral function of APOBEC3G leading us to investigate the subcellular localization of endogenous APOBEC3G in cells that serve as a natural target for HIV-1 infection. Using a rabbit polyclonal antibody directed against the C-terminus of APOBEC3G (see Materials and Methods), we immunolocalized endogenous APOBEC3G in primary CD4+ T cells isolated from peripheral blood mononuclear cells following in vitro activation (see Materials and Methods) and in H9 T lymphocytes. In both cases, endogenous APOBEC3G localized throughout the cytoplasm and to cytoplasmic bodies (Figure 1D and 1E, respectively, arrows). Both cell types typically harbored two to ten cytoplasmic bodies per cell, although imaging more than one to three per focal plane was difficult due to the rounded morphology of these cells and their random distribution throughout the cytoplasm. Importantly, these results demonstrated that the localization of APOBEC3G to cytoplasmic bodies was a bona fide property of this protein in T cells.
###end p 10
###begin p 11
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b029">29</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b030">30</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b042">42</xref>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b027">27</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b029">29</xref>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b043">43</xref>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b044">44</xref>
###xml 777 778 777 778 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 891 899 891 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g002">Figure 2</xref>
###xml 1195 1197 1195 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b035">35</xref>
###xml 1198 1200 1198 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b039">39</xref>
###xml 1210 1212 1210 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b030">30</xref>
###xml 1224 1226 1224 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b030">30</xref>
###xml 1238 1240 1238 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b027">27</xref>
###xml 1253 1255 1253 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b028">28</xref>
###xml 1258 1266 1258 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g002">Figure 2</xref>
###xml 1024 1029 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
During the course of a series of experiments to characterize the dynamics of APOBEC3G movement in living cells, we observed that cytoplasmic bodies disappeared following a 60-min incubation with cyclohexamide (unpublished data). This finding indicated that cytoplasmic bodies were not static structures but rather were both dynamic and intimately linked to mRNA translation. This dependence on active translation was a strikingly similar feature of proteins that localize to mRNA processing (P) bodies [29,30,42] which function in the degradation and storage on nontranslating mRNAs [27-29,43]. To determine if APOBEC3G cytoplasmic bodies and P-bodies were same structures, APOBEC3G and LSM1, a resident P-body protein [44], were immunolocalized in primary peripheral blood CD4+ T cells and H9 T lymphocytes. In both cases, APOBEC3G cytoplasmic bodies overlapped with LSM1-labeled P-bodies (Figure 2A, a and b, respectively, arrows), revealing that APOBEC3G localizes to P-bodies in cells that serve as a natural target for HIV-1 infection. In HeLa-APO3G cells, APO3G-Myc colocalized with endogenous LSM1 at P-bodies (unpublished data) and YFP-tagged versions of the P-body proteins LSM1, AGO2 [35,39], eIF4E [30], eIF4E-T [30], RCK/p54 [27], and DCP2 [28] (Figure 2B, a-f, respectively, arrows), and similar colocalization of these proteins with APO3G-CFP was observed in 293T cells (unpublished data). Taken together, these results clearly demonstrated that APOBEC3G cytoplasmic bodies observed in all of these different cell types were P-bodies.
###end p 11
###begin title 12
Biochemical Analysis of the Interaction between APOBEC3G and P-Body Proteins
###end title 12
###begin p 13
###xml 304 312 304 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g003">Figure 3</xref>
###xml 314 315 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g003">3</xref>
###xml 403 411 403 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g003">Figure 3</xref>
###xml 870 878 870 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g003">Figure 3</xref>
###xml 880 881 880 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g003">3</xref>
Next, we investigated whether APOBEC3G simply colocalized with these P-body proteins or if they coexisted within a complex in the cell. Using the YFP-tagged versions of the P-body proteins, we found that YFP-AGO2, YFP-eIF4E, YFP-eIF4E-T, YFP-RCK/p54, and YFP-DCP2 all coimmunoprecipitated with APO3G-HA (Figure 3B-3F, respectively). Interestingly, we could not detect coimmunoprecipitation of YFP-LSM1 (Figure 3A) or endogenous LSM1 (unpublished data) with APO3G-HA, suggesting that despite their colocalization to P-bodies these proteins do not interact in the cell. To determine if these interactions were direct or mediated through cellular RNA, the same extracts from above were also treated with RNase A prior to APO3G-HA immunoprecipitation. In all cases, coimmunoprecipitation of the YFP-tagged P-body proteins with APO3G-HA was significantly reduced by RNase A (Figure 3B-3F), suggesting that the interactions observed between APOBEC3G and AGO2, eIF4E, eIF4E-T, RCK/p54, and DCP2 were mediated through cellular RNA.
###end p 13
###begin title 14
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Potent Anti-HIV-1 Activity of APOBEC3 Proteins Correlates to P-Body Localization
###end title 14
###begin p 15
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b045">45</xref>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b051">51</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b051">51</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b055">55</xref>
###xml 55 60 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 146 151 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 333 338 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Similar to APOBEC3G, APOBEC3F is a potent inhibitor of HIV-1 replication and is targeted by Vif [45-51], while APOBEC3B exhibits only modest anti-HIV-1 activity relative to APOBEC3G and is resistant to Vif due to their inability to interact in the cell [51-55]. As a first step in characterizing the relationship between potent anti-HIV-1 function and the localization of APOBEC3G to P-bodies, we compared the subcellular localization pattern of these APOBEC3 family members.
###end p 15
###begin p 16
###xml 98 106 98 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g004">Figure 4</xref>
###xml 269 277 269 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g004">Figure 4</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b026">26</xref>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b056">56</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b057">57</xref>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b046">46</xref>
###xml 1153 1161 1149 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g004">Figure 4</xref>
Similar to APO3G-HA, APO3F-HA localized throughout the cytoplasm and to RCK/p54-labeled P-bodies (Figure 4A, a and b, respectively, arrows). Furthermore, APO3G-CFP and APO3F-HA colocalized at RCK/p54-labeled P-bodies when these proteins were coexpressed in 293T cells (Figure 4B, arrows). These results showed that APOBEC3F localizes to P-bodies and further that the localization of either APOBEC3G or APOBEC3F to P-bodies was not dependent on the other protein. Earlier findings in this study demonstrated that APOBEC3G resides in RNP complexes with other P-body proteins leading us to revisit previous observations that APOBEC3G homo-oligomerizes [26,56,57] and hetero-oligomerizes with APOBEC3F [46] to determine if these interaction were direct or mediated through cellular RNA. To address these possibilities, total cell extracts from 293T cells coexpressing either APO3G-CFP and APO3G-HA or APO3G-CFP and APO3F-HA were treated with RNase A followed by immunoprecipitation of HA-tagged protein using alpha-HA agarose. RNase A treatment virtually eliminated the coimmunoprecipitation of APO3G-CFP with APO3G-HA and APO3F-HA observed in the control (Figure 4C, top and center, respectively). These results showed that the APOBEC3G-APOBEC3G and APOBEC3G-APOBEC3F interactions previously observed through coimmunoprecipitation studies do not result from direct multimerization but rather these proteins interact through an RNA intermediate.
###end p 16
###begin p 17
###xml 160 168 160 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g004">Figure 4</xref>
###xml 266 274 266 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g004">Figure 4</xref>
###xml 468 476 468 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g004">Figure 4</xref>
###xml 1093 1103 1093 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Discussion</xref>
###xml 949 954 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
While APOBEC3G and APOBEC3F coassembled into a common RNP complex and both localized to P-bodies, APO3B-HA was largely restricted to the nucleus of 293T cells (Figure 4A, c) and rarely localized to RCK/p54-labeled P-bodies (less than 10% of cells; 500 cells scored; Figure 4A, c, arrows). Furthermore, a significant interaction between APO3G-CFP and APO3B-HA, relative to that observed for APO3G-CFP and APO3F-HA, was not detected (compare center and bottom panels in Figure 4C). However, considerable overexposure of this immunoblot did eventually reveal a weak and RNA-dependent interaction between APO3G-CFP and APO3B-HA (unpublished data). Taken together with the limited localization of APO3B-HA to P-bodies, these findings suggest that APOBEC3B is not entirely restricted from the RNP complex or P-bodies but rather is not targeted with the same efficiency as either APOBEC3G or APOBEC3F. These intriguing results suggest that the modest anti-HIV-1 activity and resistance to Vif exhibited by APOBEC3B could be linked to its inability to associate with the RNP complex and P-bodies (see Discussion).
###end p 17
###begin title 18
Vif Localizes to P-Bodies in the Presence of APOBEC3G
###end title 18
###begin p 19
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b026">26</xref>
###xml 257 262 257 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C114S</sup>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b026">26</xref>
###xml 1036 1044 1036 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g005">Figure 5</xref>
###xml 1210 1215 1210 1215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C114S</sup>
###xml 1262 1270 1262 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g005">Figure 5</xref>
###xml 1324 1329 1324 1329 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C114S</sup>
###xml 1406 1414 1406 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g005">Figure 5</xref>
###xml 1465 1470 1465 1470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C114S</sup>
###xml 1822 1830 1822 1830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g005">Figure 5</xref>
###xml 2142 2150 2142 2150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g005">Figure 5</xref>
###xml 2201 2203 2201 2203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b026">26</xref>
###xml 2278 2286 2278 2286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020041-g005">Figure 5</xref>
Recently, we reported that coexpression of Vif with APOBEC3G reduced the total cellular levels of APOBEC3G and thus limited its localization to P-bodies (referred to previously as cytoplasmic bodies [26]). In contrast, nonfunctional Vif mutants, such as VifC114S, that continued to interact with APOBEC3G readily colocalized with APOBEC3G at P-bodies [26]. These results showed that Vif was also targeted to P-bodies; however, it was not clear from those studies if the localization of Vif to P-bodies occurred independently or required the presence of APOBEC3G. To investigate these possibilities, we employed Myc-AGO2 as an internal control for P-bodies since this protein was shown to interact with APOBEC3G. The addition of Myc-AGO2 in these experiments also allowed us to examine the specificity of Vif-mediated degradation for APOBEC3G and monitor the consequence(s) of Vif expression on P-bodies. Importantly, in the presence or absence of APO3G-CFP, the steady-state levels of Myc-AGO2 were not affected by the presence of Vif (Figure 5A), demonstrating that Myc-AGO2 was not a target for Vif-mediated degradation. Subcellular localization studies further revealed that in the absence of APO3G-CFP, VifC114S did not colocalize with Myc-AGO2 at P-bodies (Figure 5B, a, arrows). However, coexpression of APO3G-CFP, VifC114S, and Myc-AGO2 resulted in colocalization of all three proteins at P-bodies (Figure 5B, b, arrows), showing that the localization of VifC114S to P-bodies was dependent on the interaction with APOBEC3G. When APO3G-CFP, Myc-AGO2, and Vif were all expressed in 293T cells, APO3G-CFP levels were reduced to below detectable levels in more than 90% of the cells that also expressed Myc-AGO2 and Vif. In cells where APO3G-CFP could not be detected, Vif did not colocalize with Myc-AGO2 at P-bodies (Figure 5B, c, arrows). However, inhibiting Vif function through a 4-h incubation with the proteasome inhibitor ALLN not only increased the levels of APO3G-CFP expression but also resulted in the colocalization of APO3G-CFP and Vif at foci that were positive for Myc-AGO2, suggesting that these structures were P-bodies (Figure 5B, d, arrows). Consistent with our previous study [26], proteasome inhibition also resulted in the nuclear localization of Vif (Figure 5B, d). Taken together, these findings demonstrated that the interaction of Vif with APOBEC3G could target Vif to P-bodies but that the proteasome-mediated degradation of APOBEC3G induced by Vif was sufficient to restrict the localization of both proteins to P-bodies. Furthermore, the rapid re-localization of APOBEC3G and Vif to P-bodies following proteasome inhibition suggested that a primary function of Vif could be to restrict the localization of APOBEC3G to P-bodies.
###end p 19
###begin title 20
Discussion
###end title 20
###begin p 21
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b001">1</xref>
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b003">3</xref>
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b004">4</xref>
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b003">3</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b010">10</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b012">12</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b015">15</xref>
###xml 430 433 430 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b018">18</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b020">20</xref>
###xml 716 721 716 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b018">18&#8211;20</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b022">22</xref>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b024">24</xref>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b058">58</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b059">59</xref>
###xml 111 116 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 444 449 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 534 539 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
According to our current understanding of APOBEC3G function, this host restriction factor limits the spread of HIV-1 infection, and other retroviruses [1,3,4], by packaging into the virus during assembly in the producer cell. Following infection of the next target cell, APOBEC3G mediates extensive dC-to-dU deamination of the viral cDNA, incomplete cDNA synthesis, and genome degradation [3,10,12-15]. Although effective against vif-deficient HIV-1, the potent antiviral activity of APOBEC3G is successfully neutralized by wild-type HIV-1 through Vif [18-20], which functions in concert with an E3 ubiquitin ligase complex to mediate the polyubiquitination and rapid degradation of APOBEC3G through the proteasome [18-20,22,24,58,59].
###end p 21
###begin p 22
###xml 274 277 274 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b026">26</xref>
###xml 749 751 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b060">60</xref>
###xml 848 851 844 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
###xml 288 293 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 862 867 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Despite these significant advances in our understanding of APOBEC3G biology, there remained a considerable lack of detail concerning the subcellular context in which APOBEC3G functions. Cell lines that are permissive (i.e., cells that do not express endogenous APOBEC3G) to vif-deficient HIV-1 replication can be rendered nonpermissive through either the transient or stable expression of recombinant APOBEC3G. Previously, we investigated the subcellular localization of recombinant APOBEC3G in these cells lines and reported that the protein localized throughout the cytoplasm and also to punctate cytoplasmic foci [26], which we termed cytoplasmic bodies in reference to the cytoplasmic bodies of another retroviral restriction factor TRIM5alpha [60]. The fact that these bodies were present under conditions that rendered cells nonpermissive to vif-deficient HIV-1 infection suggested to us that these structures could be relevant to the antiviral properties of APOBEC3G.
###end p 22
###begin p 23
###xml 127 128 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1085 1087 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b027">27</xref>
###xml 1088 1090 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b029">29</xref>
###xml 1091 1093 1087 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b061">61</xref>
###xml 1351 1353 1347 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b030">30</xref>
###xml 1391 1393 1387 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b031">31</xref>
###xml 1394 1396 1390 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b032">32</xref>
###xml 1469 1471 1465 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b035">35</xref>
###xml 1472 1474 1468 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b036">36</xref>
###xml 1475 1477 1471 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b038">38</xref>
###xml 1478 1480 1474 1476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b039">39</xref>
###xml 1481 1483 1477 1479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b062">62</xref>
###xml 1516 1518 1512 1514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b027">27</xref>
###xml 1519 1521 1515 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b028">28</xref>
###xml 1522 1524 1518 1520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b040">40</xref>
###xml 2065 2067 2061 2063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b063">63</xref>
###xml 242 247 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 978 983 <span type="species:ncbi:4932">yeast</span>
###xml 2126 2131 <span type="species:ncbi:4932">yeast</span>
###xml 2265 2270 <span type="species:ncbi:9606">human</span>
We began this study by confirming that endogenous APOBEC3G also localizes to cytoplasmic bodies in primary peripheral blood CD4+ T cells, establishing that this was a bona fide property of APOBEC3G in cells that serve as a natural target for HIV-1 infection in vivo and leading us to investigate their identity. Our initial studies revealed that APOBEC3G cytoplasmic bodies were distinct from TRIM5alpha cytoplasmic bodies and further that these bodies did not overlap with endocytic vesicles including early endosomes, late endosomes, or lysosomes (M. J. Wichroski and T. M. Rana, unpublished data). Using translation inhibitors to monitor the kinetics of cytoplasmic body assembly and disassembly, we observed that they disappeared from the cytoplasm within 60 min of cyclohexamide treatment. This dependence on active translation was a remarkably similar property of proteins that localize to mRNA processing (P) bodies, specialized compartments within the cytoplasm of both yeast and mammalian cells where nontranslating mRNAs accumulate and are subject to degradation or storage [27-29,61]. The localization of APOBEC3G to P-bodies raised the possibility that APOBEC3G could interact with other P-body proteins. Biochemical analysis showed APOBEC3G interactions with P-body proteins that function in cap-dependent translation (eIF4E and eIF4E-T [30]), translation suppression (RCK/p54 [31,32]), RNA interference-mediated post-transcriptional gene silencing (AGO2 [35,36,38,39,62]), and decapping of mRNA (DCP2 [27,28,40]). The observation that the interactions between APOBEC3G and these particular P-body proteins were all RNA dependent suggested that APOBEC3G localized to a large multiprotein RNP complex in the cell. Although the significance of the interactions mentioned above toward cellular and/or antiviral APOBEC3G functions remains to be determined, it is of considerable interest that APOBEC3G is associated with cellular machinery that mediates cytoplasmic mRNA processing events. While this manuscript was under review, Beliakova-Bethell et al. [63] reported an intriguing study linking the assembly of the yeast Ty3 retrotransposon virus-like particles with P-bodies. Therefore, it is quite possible that there is a link between the assembly of human retroviruses/retrotransposons and P-bodies.
###end p 23
###begin p 24
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b045">45</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b051">51</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b055">55</xref>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b051">51</xref>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b055">55</xref>
###xml 1431 1433 1431 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b055">55</xref>
###xml 141 146 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 252 257 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 642 647 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1229 1234 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1464 1469 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1606 1611 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Our studies on APOBEC3F and APOBEC3B revealed a possible link between the localization of APOBEC3G and APOBEC3F to P-bodies with potent anti-HIV-1 activity. APOBEC3F, which shares approximately 50% sequence identity with APOBEC3G, exhibits potent anti-HIV-1 activity, and is targeted by Vif for proteasome-mediated degradation [45-51], and both proteins are coexpressed in lymphoid cells [55]. Our results showed that APOBEC3F localizes to P-bodies and hetero-oligomerizes with APOBEC3G through an RNA-dependent interaction. On the contrary, APOBEC3B, which shares approximately 59% sequence identity with APOBEC3G, exhibits only modest anti-HIV-1 activity relative to APOBEC3G and is resistant to Vif due to their inability to interact in the cell [51-55]. Interestingly, APOBEC3B rarely localized to P-bodies and was found largely in the nucleus of 293T cells. Furthermore, significant coimmunoprecipitation of APOBEC3B with APOBEC3G was not detected, demonstrating that APOBEC3B does not localize to the same RNP complex shared by APOBEC3G and APOBEC3F. While further studies are necessary to fully assess the role of P-bodies in APOBEC3G antiviral function, these findings provide an interesting link between the potent anti-HIV-1 activities of APOBEC3G and APOBEC3F with their abilities to assemble into an RNP complex and localize to P-bodies. It is also of interest to note that APOBEC3B is not expressed in lymphoid cells [55] and thus would not encounter HIV-1 in vivo, suggesting a likely explanation as to why this protein has not evolved similarly to APOBEC3G and APOBEC3F with respect to anti-HIV-1 activity.
###end p 24
###begin p 25
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b026">26</xref>
###xml 848 853 848 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C114S</sup>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b026">26</xref>
###xml 34 39 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Considering a primary function of HIV-1 Vif is to restrict the incorporation of APOBEC3G into virions, we also determined whether Vif localized to P-bodies. Although the coexpression of Vif and APOBEC3G leads to a significant reduction in APOBEC3G levels, it is possible to detect cells where APOBEC3G and Vif are visible in the same cell [26]. In these cases, the remaining APOBEC3G rarely localized to P-bodies; however, in cases where P-body localization could be detected we noticed that Vif localized to these P-bodies as well. This observation suggested that Vif could localize to P-bodies in the presence of APOBEC3G but that the reduction in APOBEC3G levels mediated by Vif also restricted its own localization to P-bodies. This hypothesis was confirmed when it was shown that proteasome inhibition or coexpression of APOBEC3G with the Vif C114S mutant, a nonfunctional Vif mutant that continues to interact with APOBEC3G [26], led to complete colocalization of Vif and APOBEC3G at P-bodies. Interestingly, Vif did not localize to P-bodies in the absence of APOBEC3G, showing that the APOBEC3G-Vif interaction was responsible for targeting Vif to P-bodies. The finding that Vif-mediated degradation restricted the localization of both proteins to P-bodies suggests that an important role for Vif could be to selectively remove APOBEC3G from and/or prevent the association of APOBEC3G with P-bodies.
###end p 25
###begin p 26
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b001">1</xref>
###xml 109 110 109 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b003">3</xref>
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b004">4</xref>
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b005">5</xref>
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b007">7</xref>
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b007">7</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b064">64</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b067">67</xref>
###xml 621 623 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b068">68</xref>
###xml 650 652 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b069">69</xref>
###xml 196 213 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 1090 1095 <span type="species:ncbi:9606">human</span>
One of the more intriguing aspects of APOBEC3G biology is that it targets a broad range of both exogenous [1,3,4] and endogenous [5-7] retroviruses and can also limit the production of infectious hepatitis B virus [7,64-67], a DNA virus the replicates through an RNA intermediate. These findings suggest that APOBEC3G and other members of the APOBEC3 family of proteins may constitute a broad antiviral defense mechanism. This hypothesis is supported by recent findings demonstrating that the expression of APOBEC3G and other APOBEC3 family members is induced by interferon-alpha in primary monocyte-derived macrophages [68] and primary hepatocytes [69], suggesting that these proteins could be up-regulated in vivo as part of the innate immune response to viral infection. The findings that APOBEC3G and APOBEC3F are associated with mRNA processing machinery provide an important clue as to how these proteins may have evolved to exploit a common theme to protect the cell from a broad range of foreign genetic elements. Future studies would reveal the role of P bodies in the assembly of human retroviruses and retrotransposons.
###end p 26
###begin title 27
Materials and Methods
###end title 27
###begin title 28
Expression vectors and antibodies.
###end title 28
###begin p 29
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b026">26</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b054">54</xref>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b070">70</xref>
###xml 712 717 712 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C114S</sup>
###xml 787 789 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b041">41</xref>
###xml 639 644 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 830 835 <span type="species:ncbi:10090">mouse</span>
###xml 1187 1193 <span type="species:ncbi:9986">rabbit</span>
###xml 1337 1344 <span type="species:ncbi:9031">chicken</span>
APOBEC3G expression vectors pAPO3G-CFP, pAPO3G-YFP, and pAPO3G-HA were described previously [26]. Expression vectors pAPO3F-HA and pAPO3B-HA, which express APOBEC3F and APOBEC3B, respectively, with a C-terminal HA tag, were generous gifts of Dr. Bryan Cullen [54]. The pMyc-AGO2 expression vector, which expresses AGO2 with an N-terminal c-Myc epitope tag, was a generous gift of Dr. Gregory Hannon [70]. Vectors for the expression of YFP-tagged versions of LSM1 were engineered by PCR amplification of their corresponding coding sequences from 293T cDNA followed by cloning into the BglII and SalI sites of pEYFP-C1 (BD Biosciences). The HIV-1 subgenomic proviral vectors pNL-A1, pNL-A1C1, which harbors the VifC114S mutant, and pNL-A1Deltavif were generous gifts of Dr. Klaus Strebel [41]. Antibodies used in this study include mouse monoclonal antibodies alpha-GFP (BD Biosciences, San Diego, California, United States), alpha-p24 Gag (Advance Biotechnologies, Columbia, Maryland, United States), alpha-GST (Santa Cruz Biotechnology, Santa Cruz, California, United States), alpha-HA (Santa Cruz Biotechnology), and alpha-Vif (ImmunoDiagnostics, Woburn, Massachusetts, United States), rabbit polyclonal antibodies alpha-HA (Santa Cruz Biotechnology) and alpha-DDX6 (RCK/p54; Bethyl Laboratories, Montgomery, Texas, United States), and chicken polyclonal antibody alpha-LSM1 (GenWay Biotech, San Diego, California, United States). All chemicals were purchased from Sigma (St. Louis, Missouri, United States) unless otherwise indicated.
###end p 29
###begin title 30
Manipulation of mammalian cells.
###end title 30
###begin p 31
###xml 11 12 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 585 586 584 585 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1032 1034 1025 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b041">41</xref>
###xml 1216 1218 1209 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b026">26</xref>
###xml 93 98 <span type="species:ncbi:9606">human</span>
###xml 241 247 <span type="species:ncbi:9913">bovine</span>
###xml 470 475 <span type="species:ncbi:9606">human</span>
Primary CD4+ T cells were isolated (Dynal Biotech ASA, Oslo, Norway) from PHA/IL-2 activated human peripheral blood mononuclear cells cultured in RPMI 1640 medium (Invitrogen, Carlsbad, California, United States) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 mug/ml streptomycin. The H9 lymphoid T cell line (ATCC [American Type Culture Collection], Manassas, Virginia, United States) was cultured in RPMI 1640 medium modified as above. The human 293T embryonic kidney and HeLa cervical carcinoma cell lines were maintained in a humidified incubator (5% CO2) at 37 degreesC in Dulbecco's modified Eagle's medium (Invitrogen) also modified as above. The HeLa-APOBEC3G cell line (referred to here as HeLa-APO3G), which stably expresses APOBEC3G with C-terminal c-Myc epitope tag (APO3G-Myc), was obtained through the National Institutes of Health AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, from Drs. Klaus Strebel and Eri Miyagi [41]. 293T and HeLa cells were transfected with Qiagen-purified plasmid DNA (Qiagen, Valencia, California, United States) using LipofectAMINE 2000 (Invitrogen) as previously described [26].
###end p 31
###begin title 32
Immunoprecipitation and immunoblot analysis.
###end title 32
###begin p 33
###xml 398 399 398 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 1011 1013 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020041-b026">26</xref>
###xml 565 571 <span type="species:ncbi:9986">rabbit</span>
For immunoprecipitation, total cell extracts were prepared using Mammalian Protein Extraction Reagent (M-PER; Pierce, Rockford, Illinois, United States) supplemented with 0.5% (v/v) Triton-X 100 (Pierce), 150 mM NaCl, 5 mM EDTA, and a 1:100 (v/v) dilution of a protease inhibitor cocktail for mammalian tissue. Extracts were clarified by centrifugation and protein concentration was determined by Dc protein assay (Bio-Rad, Hercules, California, United States). HA and CFP tagged proteins were precipitated by overnight incubation with either alpha-HA or alpha-GFP rabbit polyclonal antibodies directly conjugated to agarose beads (Santa Cruz Biotechnology). Samples were washed four times (15 min for each wash) in lysis buffer and eluted by boiling for 2 min at 100 degreesC in SDS-PAGE sample buffer (50 mM Tris-HCl [pH 6.8], 100 mM dithiothreitol, 2% [w/v] SDS, 0.1% [w/v] bromophenol blue, 10% [v/v] glycerol). SDS-PAGE separation and immunoblot analysis of protein were performed as previously described [26].
###end p 33
###begin title 34
Immunolocalization.
###end title 34
###begin p 35
###xml 109 110 109 110 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 207 208 207 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 755 761 <span type="species:ncbi:9913">bovine</span>
For immunolocalization, 293T and HeLa cells were seeded onto glass bottom micro-well dishes coated with poly-d-lysine (MatTek Corporation, Ashland, Massachusetts, United States). Primary peripheral blood CD4+ T cells and H9 T lymphocytes were attached to cover slips using Cell-Tak cell and tissue adhesive (BD Biosciences) according to the manufacturer's instructions. Cells were fixed for 20 min with 3.7% (v/v) paraformaldehyde (Electron Microscopy Sciences, Hatfield, Pennsylvania, United States) in PBS for 20 min followed by permeabilization with 0.25% (v/v) TX-100 (Pierce) for 5 min. Samples were next washed three times (5 min for each wash) in PBS containing 0.1% (v/v) TX-100 (PBST). Samples were blocked for 30 min in PBST containing 2% (w/v) bovine serum albumin (PBST/BSA). All primary and secondary antibodies were diluted in PBST/BSA and secondary antibodies were directly conjugated to Alexa Fluor dyes (Molecular Probes, Eugene, Oregon, United States). In certain cases, samples were counterstained with Hoechst 33258 to visualize the nuclei. Samples were visualized with a Leica confocal imaging spectrophotometer system (TCS-SP2) (Exton, Pennsylvania, United States) attached to a Leica DMIRE inverted fluorescence microscope and equipped with an argon laser (458-, 476-, 488-, 514-nm lines), two HeNe lasers (543-, 633-nm lines), an acousto-optic tunable filter (AOTF) to attenuate individual visible laser lines, and a tunable acousto-optical beam splitter (AOBS). All images were acquired from a x63, 1.32 NA oil immersion objective with variable digital magnification ranging from x4 to x8, and image analysis was performed using Leica Confocal Software (LCS) and Adobe Photoshop 7.0 (Adobe Systems, Mountain View, California, United States).
###end p 35
###begin title 36
Supporting Information
###end title 36
###begin title 37
Accession Numbers
###end title 37
###begin p 38
The GenBank accession numbers () for the genes and gene products mentioned in this paper are YFP-tagged versions of LSM1 (NM_014462), AGO2 (NM_012154), eIF4E (NM_001968), eIF4E-T (NM_019843), RCK/p54 (NM_004397), and DCP2 (NM_152624).
###end p 38
###begin p 39
We thank Drs. Bryan Cullen, Gregory Hannon, and Klaus Strebel for kindly providing reagents. We thank Drs. Mario Stevenson and Jean-Marc Jacque for reagents and helpful discussions. We also thank members of the Rana laboratory for helpful discussions and critical analysis of this manuscript.
###end p 39
###begin title 40
Abbreviations
###end title 40
###begin p 41
processing body
###end p 41
###begin p 42
ribonucleoprotein
###end p 42
###begin title 43
References
###end title 43
###begin article-title 44
Retrovirus restriction factors
###end article-title 44
###begin article-title 45
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein
###end article-title 45
###begin article-title 46
###xml 58 63 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Death by deamination: A novel host restriction system for HIV-1
###end article-title 46
###begin article-title 47
Retroviral restriction by APOBEC proteins
###end article-title 47
###begin article-title 48
###xml 16 21 <span type="species:ncbi:4932">yeast</span>
###xml 45 50 <span type="species:ncbi:9606">human</span>
Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases
###end article-title 48
###begin article-title 49
APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses
###end article-title 49
###begin article-title 50
###xml 14 31 <span type="species:ncbi:10407">hepatitis B virus</span>
Inhibition of hepatitis B virus replication by APOBEC3G
###end article-title 50
###begin article-title 51
DNA deamination mediates innate immunity to retroviral infection
###end article-title 51
###begin article-title 52
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Hypermutation of HIV-1 DNA in the absence of the Vif protein
###end article-title 52
###begin article-title 53
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif
###end article-title 53
###begin article-title 54
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA
###end article-title 54
###begin article-title 55
Good to CU
###end article-title 55
###begin article-title 56
RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators
###end article-title 56
###begin article-title 57
Incorporation of uracil into minus strand DNA affects the specificity of plus strand synthesis initiation during lentiviral reverse transcription
###end article-title 57
###begin article-title 58
###xml 32 37 <span type="species:ncbi:9606">human</span>
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
###end article-title 58
###begin article-title 59
###xml 83 86 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome
###end article-title 59
###begin article-title 60
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity
###end article-title 60
###begin article-title 61
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation
###end article-title 61
###begin article-title 62
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif
###end article-title 62
###begin article-title 63
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability
###end article-title 63
###begin article-title 64
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines
###end article-title 64
###begin article-title 65
###xml 19 22 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G
###end article-title 65
###begin article-title 66
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation
###end article-title 66
###begin article-title 67
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex
###end article-title 67
###begin article-title 68
###xml 33 38 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function
###end article-title 68
###begin article-title 69
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: Correlating function and subcellular localization
###end article-title 69
###begin article-title 70
###xml 44 49 <span type="species:ncbi:9606">human</span>
Cytoplasmic foci are sites of mRNA decay in human cells
###end article-title 70
###begin article-title 71
Decapping and decay of messenger RNA occur in cytoplasmic processing bodies
###end article-title 71
###begin article-title 72
Processing bodies require RNA for assembly and contain nontranslating mRNAs
###end article-title 72
###begin article-title 73
A role for eIF4E and eIF4E-transporter in targeting mRNPs to mammalian processing bodies
###end article-title 73
###begin article-title 74
A conserved role of a DEAD box helicase in mRNA masking
###end article-title 74
###begin article-title 75
General translational repression by activators of mRNA decapping
###end article-title 75
###begin article-title 76
Disruption of GW bodies impairs mammalian RNA interference
###end article-title 76
###begin article-title 77
A role for the P-body component GW182 in microRNA function
###end article-title 77
###begin article-title 78
MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies
###end article-title 78
###begin article-title 79
Identification of novel argonaute-associated proteins
###end article-title 79
###begin article-title 80
###xml 60 65 <span type="species:ncbi:9606">human</span>
Inhibition of translational initiation by Let-7 MicroRNA in human cells
###end article-title 80
###begin article-title 81
A crucial role for GW182 and the DCP1:DCP2 decapping complex in miRNA-mediated gene silencing
###end article-title 81
###begin article-title 82
Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies
###end article-title 82
###begin article-title 83
Eukaryotic mRNA decapping
###end article-title 83
###begin article-title 84
###xml 4 39 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity
###end article-title 84
###begin article-title 85
The active form of Xp54 RNA helicase in translational repression is an RNA-mediated oligomer
###end article-title 85
###begin article-title 86
The enzymes and control of eukaryotic mRNA turnover
###end article-title 86
###begin article-title 87
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human LSm1-7 proteins colocalize with the mRNA-degrading enzymes Dcp1/2 and Xrnl in distinct cytoplasmic foci
###end article-title 87
###begin article-title 88
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 50 85 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication
###end article-title 88
###begin article-title 89
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 79 84 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins
###end article-title 89
###begin article-title 90
Complementary function of the two catalytic domains of APOBEC3G
###end article-title 90
###begin article-title 91
###xml 76 81 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
###end article-title 91
###begin article-title 92
Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities
###end article-title 92
###begin article-title 93
The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain
###end article-title 93
###begin article-title 94
Cytidine deamination of retroviral DNA by diverse APOBEC proteins
###end article-title 94
###begin article-title 95
###xml 30 33 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G
###end article-title 95
###begin article-title 96
###xml 47 76 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication
###end article-title 96
###begin article-title 97
###xml 28 49 <span type="species:ncbi:11786">murine leukemia virus</span>
Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion
###end article-title 97
###begin article-title 98
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif
###end article-title 98
###begin article-title 99
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22
###end article-title 99
###begin article-title 100
###xml 96 101 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity
###end article-title 100
###begin article-title 101
###xml 65 100 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G
###end article-title 101
###begin article-title 102
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway
###end article-title 102
###begin article-title 103
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys
###end article-title 103
###begin article-title 104
Movement of eukaryotic mRNAs between polysomes and cytoplasmic processing bodies
###end article-title 104
###begin article-title 105
A role for the P-body component GW182 in microRNA function
###end article-title 105
###begin article-title 106
Virus-like particles of the Ty3 retrotransposon assemble in association with P-body components
###end article-title 106
###begin article-title 107
###xml 24 41 <span type="species:ncbi:10407">hepatitis B virus</span>
G to A hypermutation of hepatitis B virus
###end article-title 107
###begin article-title 108
APOBEC-mediated interference with hepadnavirus production
###end article-title 108
###begin article-title 109
###xml 23 26 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Unedited inhibition of HBV replication by APOBEC3G
###end article-title 109
###begin article-title 110
###xml 26 43 <span type="species:ncbi:10407">hepatitis B virus</span>
Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo
###end article-title 110
###begin article-title 111
###xml 94 99 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity
###end article-title 111
###begin article-title 112
###xml 74 79 <span type="species:ncbi:9606">human</span>
Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes
###end article-title 112
###begin article-title 113
Argonaute2 is the catalytic engine of mammalian RNAi
###end article-title 113
###begin title 114
Figures and Tables
###end title 114
###begin title 115
APOBEC3G Localizes to Cytoplasmic Bodies
###end title 115
###begin p 116
###xml 241 242 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Subcellular localization images of living 293T cells transiently expressing APO3G-YFP (A), HeLa cells transiently expressing APO3G-YFP (B), HeLa-APO3G cells stably expressing APO3G-Myc (C), endogenous APOBEC3G in primary peripheral blood CD4+ T cells (D), and endogenous APOBEC3G in H9 T lymphocytes (E). APO3G-YFP was detected by direct YFP fluorescence while APO3G-Myc and endogenous APOBEC3G were detected by indirect immunostaining, using antibodies against the c-Myc epitope and APOBEC3G, respectively. The cells were stained with Hoechst 33258 to visualize nuclei and the imaged were merged digitally. Cell type is noted to the left of each image and arrows point to cytoplasmic bodies.
###end p 116
###begin title 117
APOBEC3G Cytoplasmic Bodies Are P-Bodies
###end title 117
###begin p 118
###xml 129 130 129 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(A) Subcellular localization of APOBEC3G and LSM1 in T cells. Endogenous APOBEC3G and LSM1 were localized in peripheral blood CD4+ T cells (a) and H9 T lymphocytes (b) through indirect immunostaining using antibodies against APOBEC3G and LSM1, respectively. The cells were counterstained with Hoechst 33258 to visualize nuclei and the images were digitally merged to highlight regions of colocalization, which appear white in the merged images. A corresponding differential interference contrast (DIC) image is presented to the left and arrows point to cytoplasmic bodies.
###end p 118
###begin p 119
(B) APOBEC3G colocalizes with P-body proteins at P-bodies. Subcellular localization of APO3G-Myc and YFP-LSM1 (a), YFP-AGO2 (b), YFP-eIF4E (c), YFP-eIF4E-T (d), YFP-RCK/p54 (e), or YFP-DCP2 (f) in HeLa-APO3G cells. APO3G-Myc was detected through indirect immunostaining with an antibody against the c-Myc epitope and YFP was detected by direct fluorescence. The cells were counterstained with Hoechst 33258 to visualize nuclei and the images were digitally merged to highlight regions of colocalization, which appear white in the merged images. Arrows point to P-bodies.
###end p 119
###begin title 120
APOBEC3G Interacts with P-Body Proteins through RNA-Dependent Interactions
###end title 120
###begin p 121
Total cell extracts from 293T cells coexpressing APO3G-HA and YFP-LSM1, YFP-AGO2, YFP-eIF4E, YFP-eIF4E-T, YFP-RCK/p54, or YFP-DCP2 (A-F, respectively) were treated with RNase A (+) or vehicle alone (-) and APO3G-HA was immunoprecipitated (IP) with alpha-HA agarose (alpha-HA IP). Total cell extracts (TCE) and alpha-HA IPs were analyzed by immunoblot, and APO3G-HA was detected with an antibody against the HA epitope, while YFP-tagged P-body proteins were detected with an antibody against GFP.
###end p 121
###begin title 122
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Potent Anti-HIV-1 Activity of APOBEC3 Proteins Correlates to P-Body Localization
###end title 122
###begin p 123
(A) Subcellular localization of endogenous RCK/p54 and APO3G-HA (a), APO3F-HA (b), or APO3B-HA (c) in 293T cells. Endogenous RCK/p54 was detected through indirect immunostaining with an antibody against RCK/p54 and APOBEC3 proteins with an antibody against the HA epitope. Arrows point to P-bodies.
###end p 123
###begin p 124
(B) Subcellular localization of endogenous RCK/p54, APO3G-CFP, and APO3F-HA in 293T cells. RCK/p54 was detected through indirect immunostaining with an antibody against RCK/p54, APO3F-HA with an antibody against the HA epitope, and APO3G-CFP was detected by direct CFP fluorescence. The cells were also stained with Hoechst 33258 to visualize nuclei and the images were digitally merged to highlight regions of colocalization, which appear white in the merged image. Arrows point to P-bodies.
###end p 124
###begin p 125
(C) RNA-dependent interaction of APOBEC3G and APOBEC3F. Total cell extracts from 293T cells coexpressing APO3G-CFP and APO3G-HA (top panel), APO3G-CFP and APO3F-HA (center panel), or APO3G-CFP and APO3B-HA (bottom panel) were treated with RNase A (+) or vehicle alone (-) and HA-tagged proteins were immunoprecipitated (IP) with alpha-HA agarose (alpha-HA IP). Total cell extracts (TCE) and alpha-HA IPs were analyzed by immunoblot and APO3G-CFP was detected using an antibody against GFP while APO3G-HA, APO3F-HA and APO3B-HA were detected using an antibody against the HA epitope.
###end p 125
###begin title 126
Localization of Vif to P-Bodies Requires APOBEC3G
###end title 126
###begin p 127
###xml 198 201 194 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vif</italic>
(A) Myc-AGO2 is not sensitive to Vif-mediated degradation in the absence or presence of APO3G-CFP. Total cell extracts from 293T cells expressing CFP or APO3G-CFP with Myc-AGO2 and either NL-A1Deltavif or NL-A1 were analyzed by immunoblot with antibodies against CFP (alpha-GFP), c-Myc (alpha-Myc) and Vif (alpha-Vif). Numbers to the left indicate molecular mass in kDa.
###end p 127
###begin p 128
###xml 96 101 96 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C114S</sup>
###xml 135 140 135 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C114S</sup>
(B) Subcellular localization images of 293T cells coexpressing a combination of Myc-AGO2 and VifC114S (a), APO3G-CFP, Myc-AGO2, and VifC114S (b), or APO3G-CFP, Myc-AGO2, and Vif following a 4-h incubation with the proteasome inhibition ALLN (d) or the equivalent DMSO vehicle control-treated cells (c). APO3G-CFP was detected by direct CFP fluorescence while Myc-AGO2 and Vif protein were detected by indirect immunostaining with antibodies against c-Myc and Vif, respectively. Arrows mark regions of colocalization or lack of colocalization between proteins.
###end p 128
###begin p 129
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. MJW and TMR conceived and designed the experiments. MJW and GBR performed the experiments. MJW, GBR, and TMR analyzed the data. GBR contributed reagents/materials/analysis tools. MJW and TMR wrote the paper.
###end p 129
###begin p 130
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 130
###begin p 131
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
###xml 164 167 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Funding. This work was supported by a grant from the National Institutes of Health to TMR. GBR is the recipient of a postdoctoral fellowship award from the Ontario HIV Treatment Network.
###end p 131
###begin p 132
###xml 48 53 <span type="species:ncbi:9606">Human</span>
Citation: Wichroski MJ, Robb GB, Rana TM (2006) Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog 2(5): e41. DOI: 10.1371/journal.ppat.0020041
###end p 132

